General manager of a British Pharmaceutical Company ViiV Healthcare in Russia Boris Charchyan shared the plan to localize production of an antiretroviral drug against AIDS (INN: dolutegravir). The drug received marketing authorization in Russia in 2014 and was approved for treatment of HIV-1 infection in adults and children from 12 years old with a body weight of ≥40 kg as part of combined antiretroviral therapy.
Studies of the drug were performed among others, in Russian medical centers.
Now full cycle of production will be organized in Russia (pharmaceutical substance will be imported). It is suggested that manufacture of the drug will be launched at the facilities of Serdix, a Russian affiliate of the French Servier.
The process of technological transfer has already begun. Probably, the manufacture of the first marketing authorization batch of the drug will start in Russia this July. Launch of the first commercial batch will probably occur at the end of next year (2017).